Francisco Esteva: HER2-targeted therapies are being explored for various other solid tumors

Francisco Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared a post on LinkedIn about a recent paper by Jeesun Yoon and Do-Youn Oh published in Nature Reviews Clinical Oncology.

“HER2-targeted therapies beyond breast cancer — an update”

“HER2-targeted therapies, initially developed for breast and gastric cancers, are now being explored for various other solid tumors.

Advancements include the use of trastuzumab deruxtecan as a new standard for treatment-refractory HER2-positive cancers, the introduction of pembrolizumab with trastuzumab and chemotherapy as a first-line option for advanced HER2-positive gastric cancer patients.

Innovative therapies and clinical trials are underway to target HER2 in diverse tumor types.”

Source: Francisco Esteva/LinkedIn

More posts featuring Francisco Esteva on oncodaily.com